human liver cancer derived hepg2 cells  (ATCC)

Journal: Antioxidants

Article Title: Myrobalan Fruit Extracts Modulate Immunobiochemical Pathways In Vitro

doi: 10.3390/antiox14030350

Figure Lengend Snippet: Effects of BB3 and the fruit extracts on cell viability. HepG2 cells were treated with vehicle (EtOH) or BB3 or myrobalan extracts (12.5–200 μg/mL) for 24 ( A ), 48 ( B ), and 72 h ( C ). Mean values ± S.E.M. of four independent experiments run in duplicates (* p < 0.05 and ** p < 0.005; compared to untreated cells) are shown.

Article Snippet: The human liver cancer-derived cell line HepG2 (RRID:CVCL_0027; DSMZ, Germany) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco—Thermo Fisher Scientific, Vienna, Austria) supplemented with 10% ( v / v ) heat-inactivated FCS.

Techniques:

Journal: Antioxidants

Article Title: Myrobalan Fruit Extracts Modulate Immunobiochemical Pathways In Vitro

doi: 10.3390/antiox14030350

Figure Lengend Snippet: Measurement of intracellular ROS. Inhibition of peroxyl-radical (AAPH)-induced formation of ROS in HepG2 cells pretreated with increasing concentrations of BB3 or the myrobalan extracts (12.5–200 μg/mL). The mean percentages of DCF fluorescence, as a measure of ROS formation, are shown in relation to the AAPH-treated EtOH vehicle control (set to 100%). Mean values ± S.E.M. of three independent experiments run in quadruplicates (** p < 0.01; compared to AAPH-treated cells) are shown.

Article Snippet: The human liver cancer-derived cell line HepG2 (RRID:CVCL_0027; DSMZ, Germany) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco—Thermo Fisher Scientific, Vienna, Austria) supplemented with 10% ( v / v ) heat-inactivated FCS.

Techniques: Inhibition, Fluorescence, Control

Journal: Antioxidants

Article Title: Myrobalan Fruit Extracts Modulate Immunobiochemical Pathways In Vitro

doi: 10.3390/antiox14030350

Figure Lengend Snippet: Influence of plant extracts on ß-lactamase activity, which was taken as a measure for ARE-dependent gene expression, in CellSensor ® ARE-bla HepG2 cells (expressed as n-fold to the corresponding control solvent). Shown are the mean values ± S.E.M. of three independent experiments with four parallels per concentration. (* p < 0.05 and ** p < 0.01; compared to vehicle-treated control cells).

Article Snippet: The human liver cancer-derived cell line HepG2 (RRID:CVCL_0027; DSMZ, Germany) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco—Thermo Fisher Scientific, Vienna, Austria) supplemented with 10% ( v / v ) heat-inactivated FCS.

Techniques: Activity Assay, Gene Expression, Control, Solvent, Concentration Assay

Journal: Antioxidants

Article Title: Protective Effects of Myricetin on Benzo[a]pyrene-Induced 8-Hydroxy-2′-Deoxyguanosine and BPDE-DNA Adduct

doi: 10.3390/antiox9050446

Figure Lengend Snippet: B[a]P and myricetin cytotoxicity in HepG2 cells. ( A , B ) HepG2 cells were treated with B[a]P (0, 1, 2.5, 5, and 10 µM) or myricetin (0, 5, 10, 20, and 40 µM) at different concentrations for 48 h. ( C ) The protective effect of myricetin against B[a]P-induced cytotoxicity was measured with B[a]P (10 μM) co-treatment with various concentrations of myricetin for 48 h. All treatment group values are significantly different when compared with controls (* p < 0.05, *** p < 0.001) and B[a]P (# p < 0.05, ### p < 0.001). Tukey’s multiple comparison test. M: myricetin.

Article Snippet: Human-derived liver cancer cells (HepG2) were purchased from the American Type Culture Collection (Manassas, VA, USA).

Techniques: Comparison

Journal: Antioxidants

Article Title: Protective Effects of Myricetin on Benzo[a]pyrene-Induced 8-Hydroxy-2′-Deoxyguanosine and BPDE-DNA Adduct

doi: 10.3390/antiox9050446

Figure Lengend Snippet: BPDE-DNA adduct concentration in B[a]P and B[a]P + myricetin treated groups. ( A ) Effect of myricetin on BPDE-DNA adduct formation in HepG2 cells following treatment with B[a]P (10 μM) and co-treatment with myricetin (10 μM) for 48 h. ( B – E ) In Sprague-Dawley rats, treatment with B[a]P (2 mg/kg) and co-treatment with myricetin (15 mg/kg) for 55 days. All treatment groups are significantly different when compared with controls (** p < 0.01, *** p < 0.001) and B[a]P (# p < 0.05, ## p < 0.01, ### p < 0.001). Tukey’s multiple comparison test. M: myricetin.

Article Snippet: Human-derived liver cancer cells (HepG2) were purchased from the American Type Culture Collection (Manassas, VA, USA).

Techniques: Concentration Assay, Comparison

Journal: Antioxidants

Article Title: Protective Effects of Myricetin on Benzo[a]pyrene-Induced 8-Hydroxy-2′-Deoxyguanosine and BPDE-DNA Adduct

doi: 10.3390/antiox9050446

Figure Lengend Snippet: The expression of phase detoxifying enzymes. ( A , B ) The effect of myricetin (15 mg/kg) and B[a]P (2 mg/kg) treatment on CYP1A1 and CYP1B1 enzyme expression in the liver of Sprague-Dawley rats. ( C ) The effect of myricetin (10 μM) and B[a]P (10 μM) treatment on CYP1A1, GST, and ABCC2 enzyme expression in HepG2 cells. ( D ) Quantitative evaluation of relative protein expression of CYP1A1, GST, and ABCC2. All treatment groups are significantly different when compared with controls (** p < 0.01, *** p < 0.001) and B[a]P (### p < 0.001). Tukey’s multiple comparison test. M: myricetin.

Article Snippet: Human-derived liver cancer cells (HepG2) were purchased from the American Type Culture Collection (Manassas, VA, USA).

Techniques: Expressing, Comparison